Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Onyx Pharmaceuticals
Criterium, Inc.
Information provided by (Responsible Party):
Academic Myeloma Consortium
ClinicalTrials.gov Identifier:
NCT01789242
First received: February 6, 2013
Last updated: July 12, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2018
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)